Scientific research papers grouped by condition

Chronic non-cancer Pain

Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS)

Mark A. Ware, Tongtong Wang, Stan Shapiro, Jean-Paul Collet Et Al.

The Journal of Pain,
2015

Study Design

Prospective cohort study for safety. 1-year follow-up. 7 clinical centers across Canada

Extract type

Whole plant extract

Cannabinoid ratio

12.5% THC

Chronic neuropathic pain

Smoked cannabis for chronic neuropathic pain: a randomized controlled trial

Ware MA1, Wang T, Shapiro S, Robinson A, Et Al.

Canadian Medical Association Journal,
2010

Study Design

Randomized, double-blind, placebo-controlled, four period (each 14 days) crossover design

Extract type

Whole plant extract

Cannabinoid ratio

2.5%, 6.0% and 9.4% THC (inhaled)

Advanced cancer patients with chronic pain unalleviated by optimized opioid therapy

Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies

Fallon MT, Albert Lux, McQuade, Rossetti Et Al.

British Journal of Pain,
2017

Study Design

Phase 3, double-blind, randomized, placebo-controlled trials. N = 399

Extract type

Whole plant extract

Cannabinoid ratio

2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray

Fibromyalgia

Medical Cannabis for the Treatment of Fibromyalgia

Habib G, Artul S

Journal of Clinical Rheumatology,
2018

Study Design

Open study. N= 26

Extract type

Whole plant extract

Cannabinoid ratio

Various

Advanced cancer and opioid-refractory pain 

Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain

Portenoy RK1, Ganae-Motan ED, Allende S, Yanagihara R Et. Al

Journal of Pain,
2012

Study Design

Randomized, double-blind, placebo-controlled, graded-dose study looking at efficacy and safety at varying doses of Sativex. N = 263

Extract type

Whole plant extract

Cannabinoid ratio

2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray

Chemotherapy-Induced Neuropathic Pain

A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain.

Lynch ME, Cesar-Rittenberg P, Hohmann AG.

Journal of Pain and Symptom Management,
2014

Study Design

A randomized, double-Blind, Placebo-Controlled, Crossover Pilot Trial With Extension. N = 16

Extract type

Whole plant extract

Cannabinoid ratio

2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray

Migraine, headache, arthritis, and chronic pain

Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort

Eric P. Baron, Philippe Lucas, Joshua Eades and Olivia Hogue

The Journal of Headache and Pain,
2018

Study Design

Uncontrolled Electronic survey

Extract type

Various

Cannabinoid ratio

Various

Advanced Cancer - Palliative Care / Appetite / Pain

Patterns of use of medical cannabis among Israeli cancer patients: a single institution experience

Waissengrin B, Urban D, Leshem Y, Garty M, Wolf I.

Journal of Pain and Symptom Management,
2015

Study Design

Observational one year study n = 279

Extract type

Various

Cannabinoid ratio

Various

Chronic non-cancer Pain

Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study

Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study

Lancet Pubic Health,
2018

Study Design

4-year prospective cohort study

Extract type

Various

Cannabinoid ratio

Various

Advanced Cancer Patients with Chronic Uncontrolled Pain

Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain

Aron H. Lichtman, Eberhard Albert Lux, Robert McQuade, Sandro Rossetti, Raymond Sanchez, Wei Sun, Stephen Wright, Elena Kornyeyeva, Marie T. Fallon.

Journal of Pain and Symptom Management,
2018

Study Design

Phase 3, double-blind, randomized, placebo-controlled trials. N = 399

Extract type

Whole plant extract

Cannabinoid ratio

2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray

Fibromyalgia

The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial

Ware MA, Fitzcharles MA, Joseph L, Shir Y.

Anesthesia & Analgesia,
2010

Study Design

Single centre, randomized, double-blind, active-control, equivalency crossover trial to compare nabilone to amitriptyline

Extract type

Sythetic THC

Cannabinoid ratio

0.5-1.0 mg

Fibromyalgia

Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life

Fiz J, Durán M, Capellà D, Carbonell J, Farré M.

PLOS One,
2011

Study Design

Uncontrolled study n = 56 (MC users vs non-users)

Extract type

Various

Cannabinoid ratio

Various

Fibromyalgia

Medical Cannabis for the Treatment of Fibromyalgia

Habib G, Artul S.

Journal of Clinical Rheumatology,
2018

Study Design

Uncontrolled study Biased selection identified from Israel Hospital registries. n = 26

Extract type

Various

Cannabinoid ratio

Various

Fibromyalgia

Nabilone for the treatment of pain in fibromyalgia

Skrabek RQ, Galimova L, Ethans K, Perry D.

Journal of Pain,
2008

Study Design

Randomized, parallel, double-blind, placebo-controlled trial n = 40

Extract type

Sythetic THC

Cannabinoid ratio

Nabilone THC

Spasticity in MS

A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex®

W Notcutt, R Langford, P Davies

Multiple Sclerosis Journal,
2013

Study Design

Placebo-controlled, parallel-group, randomized withdrawal study

Extract type

THC/CBD Extract

Cannabinoid ratio

2.7 mg THC and 2.5 mg CBD per 100 microlitre Spray (oral buccal spray)

Neuropathic pain in MS patients

Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis

Russo M, Naro A, Leo A, Sessa E, Et Al.

Pain Medicine,
2016

Study Design

Specific clinical and neurophysiological assessment

Extract type

Whole plant extract

Cannabinoid ratio

2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray

Neuropathic pain associated with multiple sclerosis

Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial

Rog DJ, Nurmikko TJ, Young CA

Clinical Therapeutics,
2007

Study Design

Uncontrolled, open-label trial extension sudy from 5 week initial RCT. 2 years. N = 28/64.

Extract type

Whole plant extract

Cannabinoid ratio

2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray

Central pain in multiple sclerosis

Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.

Rog DJ, Nurmikko TJ, Friede T, Young CA

Neurology,
2005

Study Design

Randomized, double-blind, placebo-controlled, parallel-group trial. 5 weeks study. N = 64

Extract type

Whole plant extract

Cannabinoid ratio

2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray

Multiple Sclerosis-Induced Neuropathic Pain

Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial

Turcotte D, Doupe M, Torabi M, Gomori A, Et Al.

Pain Medicine,
2015

Study Design

A single center, randomized, double-blinded, parallel, placebo-controlled study assessing Nabilone combined with Gabapentin . N = 15

Extract type

Sythetic THC

Cannabinoid ratio

2.7 µmol oral

Stable MS and muscle spasticity (short term)

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis

Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Et. Al

Lancet,
2003

Study Design

Multicenter, randomized, placebo-controlled trial. n = 630. Short term - 15 weeks

Extract type

Sythetic THC

Cannabinoid ratio

2.5 mg oral capsule

Stable MS and muscle spasticity (extension study)

Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.

Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, Et. Al

Journal of Neurology, Neurosurgery, and Psychiatry,
2005

Study Design

Multicenter, randomized, placebo-controlled trial. n =502. Extension (longer term) study - 12 months.

Extract type

Whole plant extract

Cannabinoid ratio

"2·5 mg of 9-THC equivalent, 1·25 mg of CBD, < 5% other cannabinoids / capsule "

Multiple Sclerosis (spasticity, spasms, bladder problems, tremor and pain)

Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.

Wade DT1, Makela P, Robson P, House H, Bateman C.

Multiple Sclerosis Journal,
2004

Study Design

A parallel group, double-blind, randomized, placebo-controlled study. N = 160

Extract type

Whole plant extract

Cannabinoid ratio

2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray

Multiple Sclerosis and spasticity

Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis.

Wade DT, Makela PM, House H, Bateman C, Robson P.

Multiple Sclerosis,
2006

Study Design

Open-label trial (Average 434 days) following a 10-week, placebo-controlled study. n = 137

Extract type

Whole plant extract

Cannabinoid ratio

2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray

Spasticity caused by multiple sclerosis.

Randomized controlled trial of cannabis‐based medicine in spasticity caused by multiple sclerosis

C. Collin P. Davies, Et Al. for the Sativex Spasticity in MS Study Group

European Journal of Neurology,
2007

Study Design

Randomized controlled trial n = 189

Extract type

Whole plant extract

Cannabinoid ratio

2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray

Multiple Sclerosis and spasticity

Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis

Serpell MG, Notcutt W, Collin C.

Journal of Neurology,
2013

Study Design

Six-week randomised controlled trial

Extract type

Whole plant extract

Cannabinoid ratio

2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray

Refractory MS-associated spasticity

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

Novotna A, Mares J, Ratcliffe S, Novakova I, Et Al.

European journal of neurology,
2011

Study Design

Phase 3 randomized, double-blind, placebo-controlled, parallel-group, enriched-design study. 4 week selection leading to 12 week longer study

Extract type

Whole plant extract

Cannabinoid ratio

2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray

Multiple Sclerosis and muscles stiffness

Multiple sclerosis and extract of cannabis: results of the MUSEC trial

Zajicek JP, Hobart JC, Slade A, Et Al.

J Neurol Neurosurg Psychiatry,
2012

Study Design

Multicentre, double-blind, placebo-controlled, phase III study. 12 week study. N = 279

Extract type

Cannabinoid ratio

Multiple Sclerosis - Tremor

The effect of cannabis on tremor in patients with multiple sclerosis

Fox P, Bain PG, Glickman S, Carroll C, Zajicek J.

Neurology,
2004

Study Design

Randomized double-blind placebo-controlled crossover trial. N = 14

Extract type

Whole plant extract

Cannabinoid ratio

Not stated

Multiple Sclerosis

The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis

Susan Ball, Jane Vickery, Jeremy Hobart, Dave Wright, Colin Green, James Shearer, Andrew Nunn, Mayam Gomez Cano, David MacManus, David Miller, Shahrukh Mallik, and John Zajicek

Health Technology Assessment,
2015

Study Design

Randomised, double-blind, placebo-controlled, parallel-group, multicentre trial

Extract type

Sythetic THC

Cannabinoid ratio

THC Only. Oral. Max 28mg/ml / day

Multiple Sclerosis

A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis

R. M. Langford, J. Mares, A. Novotna, M. Vachova, I. Novakova, W. Notcutt, S. Ratcliffe

Journal of neurology,
2013

Study Design

Phase III double-blinded, placebo-controlled parallel group study

Extract type

Whole plant extract

Cannabinoid ratio

2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray

Multiple Sclerosis-Induced Neuropathic Pain

Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial

Turcotte D, Doupe M, Torabi M, Gomori A, Ethans K, Esfahani F, Galloway K, Namaka M.

Pain Medicine,
2015

Study Design

A single center, randomized, double-blinded, parallel, placebo-controlled study assessing Nabilone combined with Gabapentin . N = 15

Extract type

Sythetic THC

Cannabinoid ratio

2.7 µmol oral

Pediatric epilepsy

Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy

Press CA, Knupp KG, Chapman KE.

Epilepsy & Behaviour,
2015

Study Design

Open label retrospective uncontrolled study. N = 19

Extract type

Cannabinoid ratio

Unstated. Various

Epilepsy

Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents

Hausman-Kedem M, Menascu S, Kramer U

Brain Development,
2018

Study Design

Observational uncontrolled study. N = 57. Min 3 months.

Extract type

Whole plant extract

Cannabinoid ratio

CBD/THC ratio of 20:1. (Average CBD dose 11.4 mg/kg/d). Oil

Pediatric epilepsy (treatment resistant)

Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.

Porter BE, Jacobson C

Epilepsy & Behaviour,
2013

Study Design

A retrospective uncontrolled study. N = 75

Extract type

Unstated

Cannabinoid ratio

Cannabidiol enriched - varied. (From CBD < 0.5 mg/kg/day - 28.6 mg/kg/day; THC 0 to 0.8mg/kg/day)

Pediatric epilepsy

Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients.

Treat L, Chapman KE, Colborn KL, Knupp KG

Epilepsia,
2017

Study Design

Retrospective chart review. Uncontrolled. N = 119

Extract type

Whole plant extract

Cannabinoid ratio

Oral various. Undefined

Refractory Epilepsy

Report from a Survey of Parents Regarding the Use of Cannabidiol (Medicinal cannabis) in Mexican Children with Refractory Epilepsy.

Aguirre-Velázquez CG

Neurology Research International,
2017

Study Design

Uncontrolled retrospective study. N = 53

Extract type

Various

Cannabinoid ratio

Varied. CBD 5000 mg /CBD 1000 mg, CBD + THC 5000mg/CBD + THC 500mg/ Other CBD/THC

Dravet Syndrome

A prospective open-label trial of a CBD/THC cannabis oil in dravet syndrome

Blathnaid McCoy, Laura Wang, Maria Zak, Sameer Al-Mehmadi, Nadia Kabir1 Kenda Alhadid, Kyla McDonald, Grace Zhang, Rohit Sharma, Robyn Whitney, Katia Sinopoli & O. Carter Snead III

Annals of Clinical and Translational Neurology,
2018

Study Design

Extract type

Whole plant extract

Cannabinoid ratio

100mg CBD : 2 mg THC (TIL-TC150)

Dravet Syndrome

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.

Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S

New England Journal of Medicine,
2017

Study Design

A multinational, randomized, double-blind trial. N = 120. 14 week treatment

Extract type

Whole plant extract

Cannabinoid ratio

CBD only (20 mg/kg bw) oral

Treatment-resistant epilepsy

Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial

Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, Miller I, Flamini R, Wilfong A, Filloux F, Wong M, Tilton N, Bruno P, Bluvstein J, Hedlund J, Kamens R, Maclean J, Nangia S5, Singhal NS, Wilson CA, Patel A, Cilio MR.

Lancet Neurology,
2016

Study Design

Open-label uncontrolled interventional trial

Extract type

Whole plant extract

Cannabinoid ratio

CBD only (2.5-25/50 mg/kg bw) oral

Lennox-Gastaut syndrome

Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome

Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM; GWPCARE3 Study Group

New england journal of medicine,
2018

Study Design

Double-blind, placebo-controlled trial. 14 weeks. N =225

Extract type

Whole plant extract

Cannabinoid ratio

CBD only (10 or 25 mg/kg bw) oral

Lennox-Gastaut syndrome

Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial

Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K; GWPCARE4 Study Group.

Lancet,
2018

Study Design

Extract type

Whole plant extract

Cannabinoid ratio

CBD only (20 mg/kg bw) oral

Pediatric epilepsy

CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience

Tzadok M, Uliel-Siboni S, Linder I, Kramer U, Epstein O, Menascu S, Nissenkorn A, Yosef OB, Hyman E, Granot D, Dor M, Lerman-Sagie T, Ben-Zeev B.

Seizure,
2016

Study Design

Retrospective uncontrolled study. N = 74

Extract type

Whole plant extract

Cannabinoid ratio

20 CBD : 1 THC

Epilepsy

Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients

Cunha J.M., Carlini E.A., Pereira A.E., Ramos O.L., Pimentel C., Gagliardi R., Sanvito W.L., Lander N., Mechoulam R

Pharmacology,
1980

Study Design

Double-blind, placebo-controlled trial. N = 15. Up to 4.5 months

Extract type

Whole plant extract

Cannabinoid ratio

CBD (200-300mg)

CINV

Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting

Br J Clin Pharmacol

British Journal of Clinical Pharmacology,
2010

Study Design

Pilot, randomized, double-blind, placebo-controlled phase II clinical trial assessing tolerability, preliminary efficacy, and pharmacokinetics of Whole plant medicine in conjuction with standard treatment. N = 16

Extract type

Whole plant extract

Cannabinoid ratio

2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray

CINV

Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting

Lane M, Vogel CL, Ferguson J, Krasnow S, Et Al.

Journal of Pain and Symptom Management,
1991

Study Design

Randomized, double-blind, parallel group, multicenter study. Assessing combination treatment of Dronabinol and prochlorperazine

Extract type

Sythetic THC

Cannabinoid ratio

2.5% THC oil

Delayed CINV

Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting

Meiri E, Jhangiani H, Vredenburgh JJ, Et Al.

Current Medical Research and Opinion,
2007

Study Design

Randomized, double blinded, placebo- controlled parallel group 5 day trial n = 64

Extract type

Sythetic THC

Cannabinoid ratio

2.5 mg oral capsule

CINV

Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting

Duran M, Pérez E, Abanades S, Vidal X, Et Al.

British Journal of Clinical Pharmacology,
2010

Study Design

Pilot, randomized,double-blind, placebo-controlled phase II clinical trial. N = 16

Extract type

Whole plant extract

Cannabinoid ratio

2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray

Nausea and Vomiting in Peritoneal Carcinomatosis (unrelated to Chemotherapy)

Dronabinol Treatment of Refractory Nausea and Vomiting Related to Peritoneal Carcinomatosis

Sarah L Hernandez, Inna Shayner, Karen T Stover, Et Al.

American Journal of Hospice and Palliative Medicine,
2013

Study Design

Case study (Pt with end-stage ovarian cancer with peritoneal carcinomatosis and refractory nausea and vomiting)

Extract type

Sythetic THC

Cannabinoid ratio

2.5 mg oral capsule

CINV

Cannabinoids in the management of intractable chemotherapy-induced nausea and vomiting and cancer-related pain

Sutton IR, Daeninck P

The Journal of Supportive Oncology,
2006

Study Design

Survey; Uncontrolled case reports. 1. Refractory CINV and 2. Intractable Pain

Extract type

Sythetic THC

Cannabinoid ratio

2.5 mg oral capsule

CINV

The Medical Necessity for Medicinal Cannabis: Prospective, Observational Study Evaluating the Treatment in Cancer Patients on Supportive or Palliative Care

Gil Bar-Sela, Marina Vorobeichik, Saher Drawsheh, Anat Omer, Victoria Goldberg, and Ella Muller

Evidence-Based Complementary and Alternative Medicine,
2013

Study Design

Prospective, Observational Study. Interview questions and data collection. 6-8 week Tx. N= 106 (selected bias group continuing Tx)

Extract type

Various

Cannabinoid ratio

Various

CINV

Randomized double-blind evaluation of dronabinol for the prevention of chemotherapy-induced nausea

Steven M. Grunberg, Mark F. Munsell, Phuong Khanh H. Morrow, Jeffrey Kent Giguere, Ulla Jo Ule, Steven J. Saccaro, Adedayo A. Onitilo, Joanna K. Metzner-Sadurski, Michael Fisch

Journal of Clinical Oncology,
2012

Study Design

Randomized double-blind study. N = 62

Extract type

Synthetic Cannabinoid

Cannabinoid ratio

5mg Synthetic Cannabinoid

Advanced Cancer Patients with Chronic Uncontrolled Pain

Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain

Aron H. Lichtman, Eberhard Albert Lux, Robert McQuade, Sandro Rossetti Et Al.

Journal of Pain and Symptom Management,
2018

Study Design

Double-blind, Randomized, Placebo-Controlled Study.

Extract type

Whole plant extract

Cannabinoid ratio

2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray

Pallative care cancer patients

The Medical Necessity for Medicinal Cannabis: Prospective, Observational Study Evaluating the Treatment in Cancer Patients on Supportive or Palliative Care

Gil Bar-Sela, Marina Vorobeichik, Saher Drawsheh, Anat Omer, Victoria Goldberg, and Ella Muller

Evidence-Based Complementary and Alternative Medicine,
2013

Study Design

Prospective, Observational Study. Interview questions and data collection. 6-8 week Tx. N= 106 (selected bias group continuing Tx)

Extract type

Various

Cannabinoid ratio

Various

Terminal Cancer-Related Pain (Moderate / Severe) Refractory to Strong Opioid Analgesics

Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain

Johnson JR1, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Et Al.

Journal of Pain and Symptom Management,
2010

Study Design

Two-week, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial (GW Pharma Ltd). N= 177

Extract type

Whole plant extract

Cannabinoid ratio

2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray

Terminal Cancer-Related Pain Refractory to Strong Opioid Analgesics

An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics

Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT.

Journal of Pain and Symptom Management,
2013

Study Design

Open-Label Extension Study from original 2 week RCT study. N = 43.

Extract type

Whole plant extract

Cannabinoid ratio

2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray

Chemotherapy-Induced Neuropathic Pain

A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain.

Lynch ME, Cesar-Rittenberg P, Hohmann AG.

Journal of Pain and Symptom Management,
2014

Study Design

A randomized, double-Blind, Placebo-Controlled, Crossover Pilot Trial With Extension. N = 16

Extract type

Whole plant extract

Cannabinoid ratio

2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray

Advanced Cancer - Palliative Care / Appetite / Pain

Patterns of use of medical cannabis among Israeli cancer patients: a single institution experience

Waissengrin B, Urban D, Leshem Y, Garty M, Wolf I.

Journal of Pain and Symptom Management,
2015

Study Design

Observational one year study n = 279

Extract type

Various

Cannabinoid ratio

Various

Fibromyalgia

Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief

Schley M, Legler A, Skopp G, Schmelz M, Konrad C, Rukwied R.

Current Medical Research and Opinion,
2006

Study Design

Uncontrolled pilot sudy (n= 9)

Extract type

Unstated

Cannabinoid ratio

2.5-15 mg of delta-9-THC

Cancer Pain / Palliative

Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial

Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S, McQuade R, Wright S, Fallon MT

Journal of Pain,
2012

Study Design

Randomized, placebo-controlled, graded-dose trial. N = 360

Extract type

Whole plant extract

Cannabinoid ratio

2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray

Refractory human diabetic peripheral neuropathic pain (DPN)

Refractory human diabetic peripheral neuropathic pain (DPN)

Toth C, Mawani S, Brady S, Chan C, Liu C, Et Al.

Pain,
2012

Study Design

Single-center, randomized, double-blind, placebo-controlled, flexible-dose study with an enriched enrollment randomized withdrawal design.

Extract type

Sythetic THC

Cannabinoid ratio

2.7 µmol oral

Neuropathic pain (Pts with peripheral neuropathy)

An open-label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy

Bestard JA, Toth CC.

Pain Practice,
2011

Study Design

Open‐Label Comparison Trial to compare the efficacy of nabilone as either monotherapy or adjuvant therapy with a first‐line medication (gabapentin)

Extract type

Sythetic THC

Cannabinoid ratio

2.7 µmol oral

Chronic neuropathic pain

Smoked cannabis for chronic neuropathic pain: a randomized controlled trial

Ware MA1, Wang T, Shapiro S, Robinson A, Et Al.

Canadian Medical Association Journal,
2010

Study Design

Randomized, double-blind, placebo-controlled, four period (each 14 days) crossover design

Extract type

Whole plant extract

Cannabinoid ratio

2.5%, 6.0% and 9.4% THC (inhaled)

Neuropathic pain in MS patients

Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis

Russo M, Naro A, Leo A, Sessa E, Et Al.

Pain Medicine,
2016

Study Design

Specific clinical and neurophysiological assessment

Extract type

Whole plant extract

Cannabinoid ratio

2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray

Neuropathic pain associated with multiple sclerosis

Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial

Rog DJ, Nurmikko TJ, Young CA

Clinical Therapeutics,
2007

Study Design

Uncontrolled, open-label trial extension sudy from 5 week initial RCT. 2 years. N = 28/64.

Extract type

Whole plant extract

Cannabinoid ratio

2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray

Multiple Sclerosis-Induced Neuropathic Pain

Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial

Turcotte D, Doupe M, Torabi M, Gomori A, Et Al.

Pain Medicine,
2015

Study Design

A single center, randomized, double-blinded, parallel, placebo-controlled study assessing Nabilone combined with Gabapentin . N = 15

Extract type

Sythetic THC

Cannabinoid ratio

2.7 µmol oral

Neuropathic Pain (central and peripheral)

Low-dose vaporized cannabis significantly improves neuropathic pain.

Wilsey B1, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H.

The Journal of Pain,
2013

Study Design

Randomized, double-blind, placebocontrolled, crossover design. N = 39

Extract type

Whole Plant Extract (Vapourised)

Cannabinoid ratio

medium-dose (3.53% THC), low-dose (1.29% THC)

Chemotherapy-Induced Neuropathic Pain

A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain.

Lynch ME, Cesar-Rittenberg P, Hohmann AG.

Journal of Pain and Symptom Management,
2014

Study Design

A randomized, double-Blind, Placebo-Controlled, Crossover Pilot Trial With Extension. N = 16

Extract type

Whole plant extract

Cannabinoid ratio

2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray

Neuropathic Pain in HIV (HIV-associated distal sensory predominant polyneuropathy (DSPN)

Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial.

Ellis RJ, Toperoff W, Vaida F, van den Brande G, Gonzales J, Et. Al

Neuropsychopharmacology,
2009

Study Design

Phase II, double-blind, placebo-controlled, crossover trial assessing analgesia with smoked cannabis in HIV-associated distal sensory predominant polyneuropathy (DSPN). N =28

Extract type

Whole plant extract

Cannabinoid ratio

THC strengths ranging 1% - 8% conc by weight. CBD not reported. Smoked

Multiple Sclerosis-Induced Neuropathic Pain

Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial

Turcotte D, Doupe M, Torabi M, Gomori A, Ethans K, Esfahani F, Galloway K, Namaka M.

Pain Medicine,
2015

Study Design

A single center, randomized, double-blinded, parallel, placebo-controlled study assessing Nabilone combined with Gabapentin . N = 15

Extract type

Sythetic THC

Cannabinoid ratio

2.7 µmol oral

Neurogenic pain

A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms

Derick T Wade, Philip Robson,Petra Makela and Julia Aram

Clinical Rehabilitation,
2003

Study Design

Pilot double-blind cross-over study. N = 20

Extract type

Whole plant extract

Cannabinoid ratio

2.5mg THC : 2.5mg CBD sublingual spray

Neuropathic Pain

A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis

R. M. Langford, J. Mares, A. Novotna, M. Vachova, I. Novakova, W. Notcutt, S. Ratcliffe

Journal of neurology,
2013

Study Design

Phase III double-blinded, placebo-controlled parallel group study

Extract type

Whole plant extract

Cannabinoid ratio

2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray

Peripheral Neuropathic Pain

A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment

Serpell M, Ratcliffe S, Hovorka J, Schofield M, Taylor L, Lauder H, Ehler E

European Journal of Pain,
2014

Study Design

Phase III double-blinded, placebo-controlled parallel group study

Extract type

Whole plant extract

Cannabinoid ratio

2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray

Parkinson's Disease

Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study.

Itay Lotan; Therese A. Treves; Yaniv Roditi; Ruth Djaldetti

Clinical Neuropharmacology,
2014

Study Design

Uncontrolled. Open label n = 22

Extract type

Smoked cannabis

Cannabinoid ratio

0.5 g cannabis

Parkinson’s disease

Cannabidiol for the treatment of psychosis in Parkinson’s disease

Zuardi AW, Crippa JA, Hallak JE, Pinto JP, Chagas MH, Rodrigues GG, Dursun SM, Tumas V

Journal of Psychopharmacology,
2009

Study Design

Open label case series n = 6

Extract type

CBD (Undefined)

Cannabinoid ratio

CBD only. Oral capsule

Parkinson disease:

Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study.

Carroll CB, Bain PG, Teare L, Liu X, Joint C, Wroath C, Parkin SG, Fox P, Wright D, Hobart J, Zajicek JP

Neurology,
2004

Study Design

Randomized, double-blind, placebo-controlled crossover trial. N = 19

Extract type

Whole plant extract

Cannabinoid ratio

1.25 mg CBD and 2.5 mg THC

Parkinson's disease

Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease.

Mesnage V, Houeto JL, Bonnet AM, Clavier I, Arnulf I, Cattelin F, Le Fur G, Damier P, Welter ML, Agid Y

Clinical Neuropharmacology,
2004

Study Design

Randomized, double-blind, placebo-controlled trial. N = 8

Extract type

Synthetic Cannabinoid

Cannabinoid ratio

Selective central (CB1) cannabinoid receptor antagonist

Parkinson's disease

Survey on Cannabis Use in Parkinson’s Disease: Subjective Improvement of Motor Symptoms

Venderová K, Růzicka E, Vorísek V, Visnovský P

Movement Disorders,
2004

Study Design

Uncontrolled questionnaire

Extract type

Various

Cannabinoid ratio

Various

Parkinson's disease

Effects of cannabidiol in the treatment of patients with Parkinson's disease: An exploratory double-blind trial.

Chagas MH, Zuardi AW, Tumas V, Pena-Pereira MA, Sobreira ET, Bergamaschi MM, dos Santos AC, Teixeira AL, Hallak JE, Crippa JA

Journal of Psychopharmacology,
2014

Study Design

Exploratory randomized, double-blind, placebo-controlled trial n = 22.

Extract type

Unstated

Cannabinoid ratio

CBD 75 or 300 mg/day

Parkinson's disease

Cannabinoids reduce levodopa induced dyskinesia in Parkinson’s disease: a pilot study

Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM

Neurology,
2001

Study Design

Randomized, double-blind, placebo-controlled, crossover trial. n = 7

Extract type

Synthetic Cannabinoid

Cannabinoid ratio

Not stated

Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients

A case series.

Chagas MH, Eckeli AL, Zuardi AW, Pena-Pereira MA, Sobreira-Neto MA, Sobreira ET, Camilo MR, Bergamaschi MM, Schenck CH, Hallak JE, Tumas V, Crippa JA.

Journal of Clinical Pharmacy and Therapeutics,
2014

Study Design

Case series n = 4

Extract type

CBD (Undefined)

Cannabinoid ratio

CBD only. Oral capsule

Parkinson's disease

Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: A case series.

Chagas MH, Eckeli AL, Zuardi AW, Pena-Pereira MA, Sobreira-Neto MA, Sobreira ET, Camilo MR, Bergamaschi MM, Schenck CH, Hallak JE, Tumas V, Crippa JA.

Journal of Clinical Pharmacy and Therapeutics,
2014

Study Design

Case series n = 4

Extract type

CBD (Undefined)

Cannabinoid ratio

CBD only. Oral capsule

Cancer-Related Anorexia-Cachexia Syndrome

Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment Group Study

Aminah Jatoi, Harold E. Windschitl, Charles L. Loprinzi, Jeff A. Sloan, Shaker R. Dakhil, James A. Mailliard, Sarode Pundaleeka, Carl G. Kardinal, Tom R. Fitch, James E. Krook, Paul J. Novotny, and Brad Christensen

Journal of Clinical Oncology,
2002

Study Design

Multi-institutional, double-blind, randomized trial. N = 469

Extract type

Synthetic Cannabinoid

Cannabinoid ratio

2.5mg Capsule

Cancer-related anorexia-cachexia syndrome (CACS)

Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome

Cannabis-In-Cachexia-Study-Group1, Strasser F, Luftner D, Possinger K Et. Al

JOURNAL OF CLINICAL ONCOLOGY,
2006

Study Design

Multicenter, phase III, randomized, double-blind, placebo (PL)-controlled, three-arm, parallel study. N = 243

Extract type

Whole plant extract

Cannabinoid ratio

2.5 mg THC : 1 mg CBD capsules and 2.5 mg THC capsules

Cancer- Cachexia

Patterns of use of medical cannabis among Israeli cancer patients: a single institution experience

Waissengrin B, Urban D, Leshem Y, Garty M, Wolf I.

Journal of Pain and Symptom Management,
2015

Study Design

Observational one year study n = 279

Extract type

Various

Cannabinoid ratio

Various - uncontrolled

Cancer-Related Anorexia

The Efficacy and Tolerability of Long-Term Use of Dronabinol in Cancer-Related Anorexia: A Case Series

Walsh D, Kirkova J, Davis MP.

Journal of Pain and Symptom Management,
2005

Study Design

Uncontrolled. Case Series

Extract type

Various

Cannabinoid ratio

Various Uncontrolled

Pallative care cancer patients

The Medical Necessity for Medicinal Cannabis: Prospective, Observational Study Evaluating the Treatment in Cancer Patients on Supportive or Palliative Care

Gil Bar-Sela, Marina Vorobeichik, Saher Drawsheh, Anat Omer, Victoria Goldberg, and Ella Muller

Evidence-Based Complementary and Alternative Medicine,
2013

Study Design

Prospective, Observational Study. Interview questions and data collection. 6-8 week Tx. N= 106 (selected bias group continuing Tx)

Extract type

Various

Cannabinoid ratio

Various

Pediatric palliative care

Treatment resistant refractory spasticity in pediatric palliative care

Michaela Kuhlen, Jessica I. Hoell, Gabriele Gagnon, Stefan Balzer

European Journal of Paediatric Neurology,
2016

Study Design

Open, uncontrolled, retrospective study measuring value, efficacy, and safety

Extract type

Synthetic

Cannabinoid ratio

Dronabinol -Synthetic THC. 2.5% THC oil

Treatment resistant refractory spasticity in pediatric palliative care

Effective treatment of spasticity using dronabinol in pediatric palliative care

Michaela Kuhlen , Jessica I. Hoell, Gabriele Gagnon, Et Al.

European Journal of Paediatric Neurology,
2016

Study Design

Open, uncontrolled, retrospective study measuring value, efficacy, and safety. N=16. Median duration 181 days

Extract type

Sythetic THC

Cannabinoid ratio

2.5% THC oil

Advanced Cancer - Palliative Care / Appetite / Pain

Patterns of use of medical cannabis among Israeli cancer patients: a single institution experience

Waissengrin B, Urban D, Leshem Y, Garty M, Wolf I.

Journal of Pain and Symptom Management,
2015

Study Design

Observational one year study n = 279

Extract type

Various

Cannabinoid ratio

Various

Advanced Cancer Patients with Chronic Uncontrolled Pain

Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain

Aron H. Lichtman, Eberhard Albert Lux, Robert McQuade, Sandro Rossetti, Raymond Sanchez, Wei Sun, Stephen Wright, Elena Kornyeyeva, Marie T. Fallon,

Journal of Pain and Symptom Management,
2018

Study Design

Phase 3 Double-Blind, Randomized, Placebo-Controlled Study. N=397. Self-titrated study medications over a two-week period, followed by a three-week treatment period at the titrated dose.

Extract type

Whole plant extract

Cannabinoid ratio

2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray

Cancer Pain / Palliative

Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial

Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S, McQuade R, Wright S, Fallon MT

Journal of Pain,
2012

Study Design

Randomized, placebo-controlled, graded-dose trial. N = 360

Extract type

Whole plant extract

Cannabinoid ratio

2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray

Palliative Care

Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial

Brisbois TD, de Kock IH, Watanabe SM, Mirhosseini M, Lamoureux DC, Chasen M, MacDonald N, Baracos VE, Wismer WV.

Annals of Oncology ,
2011

Study Design

Randomized, double-blind, placebo-controlled pilot trial. N = 46

Extract type

Synthetic Cannabinoid

Cannabinoid ratio

2.5 mg oral capsule

Chronic PTSD

Preliminary, Open-Label, Pilot Study of Add-On Oral Δ9-Tetrahydrocannabinol in Chronic Post-Traumatic Stress Disorder

Pablo Roitman, Raphael Mechoulam, Rena Cooper-Kazaz, Arieh Shalev

Clinical Drug Investigation,
2014

Study Design

Pilot, open-label study on tolerance and safety. N = 10. THC as an add on Therapy

Extract type

Synthetic

Cannabinoid ratio

Oral

PTSD

The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study

Jetly R, Heber A, Fraser G, Boisvert D

Psychoneuroendocrinology,
2015

Study Design

Randomized, double-blind, placebo-controlled cross-over design study. N = 10. 7-2-7 week study treatments

Extract type

Sythetic THC

Cannabinoid ratio

0.5mg-3 mg oral capsule

PTSD 1

Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation

 Cameron C, Watson D, Robinson J

Journal of Clinical Psychopharmacology,
2014

Study Design

Uncontrolled retroscpective study - patients at least a single dose of nabilone for any indication from January 1, 2010, to July 31, 2013 (n = 104)

Extract type

Sythetic THC

Cannabinoid ratio

Various - powder in water

PTSD and Substance Use Disorders

Impact of Cannabis Use on Treatment Outcomes among Adults Receiving Cognitive-Behavioral Treatment for PTSD and Substance Use Disorders

Ruglass LM, Shevorykin A, Radoncic V, Smith KM, Smith PH, Et Al.

Journal of Clinical Medicine,
2017

Study Design

Uncontrolled study with Multivariate regression analyses and multilevel linear growth models

Extract type

Whole plant extract

Cannabinoid ratio

Various - uncontrolled